Home > Boards > US Listed > Real Estate > Bluth Company (BLU)

6-K Out last night...

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
I-Man Member Profile
 
Followed By 68
Posts 8,373
Boards Moderated 0
Alias Born 12/05/07
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/13/2021 7:00:54 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/8/2021 10:17:03 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/5/2021 11:44:01 AM
Annual Report (foreign Private Issuer) (40-f) Edgar (US Regulatory) - 2/25/2021 5:01:11 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/25/2021 4:03:49 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/22/2021 7:00:57 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 3:16:25 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 7:33:37 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 6:38:24 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 9:38:09 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 6:04:19 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/8/2021 10:18:47 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/14/2021 7:01:35 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 12/28/2020 6:51:34 AM
Voluntary Supplemental Material Filed Pursuant to Section 11(a) of the Securities Act of 1933 by Foreign Issuers (suppl) Edgar (US Regulatory) - 12/23/2020 5:02:31 PM
Amended Registration Statement for Securities of Certain Canadian Issuers Under the Securities Act of 1933 (f-10/a) Edgar (US Regulatory) - 12/23/2020 4:07:28 PM
Appointment of Agent for Service of Process and Undertaking (f-x) Edgar (US Regulatory) - 12/14/2020 4:41:09 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/14/2020 7:01:35 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/8/2020 7:01:26 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/7/2020 7:02:11 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 4:10:48 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 7:02:19 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/10/2020 7:01:25 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/23/2020 5:21:41 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/20/2020 4:43:44 PM
I-Man   Tuesday, 02/23/21 06:49:51 AM
Re: richrichrich post# 445
Post # of 451 
6-K Out last night...

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.

Chronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with approximately 3 million having refractory chronic cough lasting for more than a year and approximately 6 million having refractory chronic cough lasting more than 8 weeks and under one year. There is no specific therapy approved for refractory chronic cough and current treatment options are limited.

Chronic pruritus, the second indication for BLU-5937, is commonly known as chronic itch and is an irritating sensation that leads to scratching and persists for longer than six weeks, which can be debilitating and can significantly impact quality of life. It is a hallmark of many inflammatory skin diseases, including atopic dermatitis (“AD”). It is estimated that AD afflicts approximately 5% of adults in the United States. Despite currently available treatments targeting AD, there continues to be a lack of options targeting the burden of pruritus in AD patients.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences